Skip to main content
BioCentury on BioBusiness
Feature Story

Cover Story: Politics, Policy & Law: Duck and cover

Why biopharma is taking the risky approach of waiting for Trump to focus elsewhere

By Steve Usdin, Washington Editor

Biopharmaceutical industry CEOs and lobbyists tell BioCentury they have settled on a duck and cover strategy for coping with President-elect Donald Trump's frontal attacks on the industry's pricing policies and global supply chains.

The idea is to avoid antagonizing Trump by directly responding to him or launching an aggressive public defense, while quietly shoring up alliances with lawmakers whose votes would be needed to implement the most drastic drug price-control proposals.

Read Article

Today's Biotech & Pharma News

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial